It’s been ten years since the doctors told him he was about to die.

You are invited to join a LiveStream Question & Answer Session with me, Joe.

I've kept asking questions, learning more, and doing research, which has helped me clarify my thoughts and experiences. Come see for yourself.
I will answer questions asked during the broadcast, directly from you!

Live Webinar Question & Answer Session:
September 29th at 12 pm PST / 2 pm CST

Please use this link to register: CLICK HERE or the image below

https://vimeo.com/event/6194983

The page will be expanded weekly. If you have a resource and want to be listed, email us fenbendazolecancer@gmai.com

Resources URL

https://start.me/p/gGo6vz/fenbendazole-cancer-resources

To overcome the low aqueous solubility and limited gastrointestinal absorption of benzimidazole anthelmintics, researchers have developed engineered formulated delivery systems. These nanocarriers transform hydrophobic benzimidazoles into stable, bioavailable therapeutics that reach effective systemic concentrations in vivo.

1. Albumin Nanoparticles (Nab Platform & BSA Complexes)

Albumin-based nano-formulations utilize natural endocytic transport pathways (such as gp60/caveolin-1 receptor-mediated transcytosis) to accumulate in tumor tissue:

• Ovarian Cancer Control: Unformulated, free albendazole shows little antitumor activity in ovarian cancer models, whereas bovine serum albumin-conjugated albendazole (BSA-ABZ) and nano-albumin albendazole (Nab-ABZ) significantly reduce tumor weight, suppress malignant ascites accumulation, and inhibit VEGF-driven angiogenesis in vivo.

• Photothermal Bladder Cancer Therapy (FBZ@BSA@PDA): Thermally encapsulating fenbendazole in bovine serum albumin, followed by in situ polydopamine polymerization, creates FBZ@BSA@PDA nanoparticles. Used as a localized intravesical instillation for bladder cancer, this platform enhances drug retention and triggers localized photothermal-enhanced ferroptosis, glutathione (GSH) depletion, and immunogenic cell death (ICD) markers (calreticulin exposure, HMGB1 release, and ATP secretion).

2. Cyclodextrin Inclusion Complexes

Cyclodextrins form host-guest inclusion complexes that encapsulate lipophilic benzimidazole molecules within their hydrophobic cavities while exposing a hydrophilic outer surface:

• Methyl-\(\beta\)-Cyclodextrin (Methyl-\(\beta\)-CD): Complexing fenbendazole with methyl-\(\beta\)-cyclodextrin at a 1:1 ratio increases water solubility to 20.21 mg/mL—a 60,000-fold enhancement over pure drug powder. This inclusion complex elevates the initial 15-minute drug release rate from 5% to 75%.

• Hydroxypropyl-\(\beta\)-Cyclodextrin (HP-\(\beta\)-CD): Complexing albendazole with HP-\(\beta\)-CD markedly improves its systemic pharmacokinetic profile, enhancing in vitro cell cytotoxicity and in vivo antitumor efficacy in tumor-bearing mice.

3. Polymeric Micelles & Amorphous Solid Dispersions

Dispersing benzimidazoles into amphiphilic polymer matrices disrupts their stable crystal lattice, locking the drug into an amorphous state with rapid dissolution kinetics:

• Soluplus® Amorphous Solid Dispersions: Formulating fenbendazole with the amphiphilic copolymer Soluplus® via hot-melt extrusion (HME) converts crystalline fenbendazole into an amorphous solid dispersion. In acidic media (pH 1.2), a 5% Soluplus® extrudate elevates cumulative drug dissolution from 20% (neat drug) to ~85%. Injectable Soluplus® polymeric micelles also reduce total systemic clearance while increasing overall AUC.

• mPEG-b-PCL Co-Loaded Micelles (M-FR): Freeze-dried mPEG-b-PCL polymeric micelles co-encapsulating fenbendazole and rapamycin (M-FR) significantly improve systemic bioavailability and reduce ovarian cancer cell proliferation compared to unformulated dual-drug suspensions.

4. PLGA & Chitosan Polymeric Nanoparticles

Biodegradable synthetic and natural polymers provide sustained, targeted release profiles:

• PLGA Nanoparticles (FZ-PLGA-NPs): Encapsulating fenbendazole into poly(D, L-lactide-co-glycolide) acid nanoparticles (FZ-PLGA-NPs) enables intravenous administration, producing marked tumor weight reductions and antiproliferative activity across epithelial ovarian cancer (EOC) xenografts and patient-derived xenograft (PDX) models.

• Chitosan-Tripolyphosphate Nanoparticles: Chitosan-based nanoparticulate systems loaded with albendazole enhance cellular uptake and mucosal adhesion.

5. Lipid Nanocarriers, Nanoemulsions & Nanocrystals

• Solid Lipid Nanoparticles (SLNs): Albendazole-loaded solid lipid nanoparticles demonstrate enhanced cellular uptake and cytotoxicity against U-87 MG human glioblastoma cells.

• Flubendazole Nanoemulsions & Nanocrystals: Engineering flubendazole into high-oil nanoemulsions or nanocrystals significantly improves systemic drug exposure and successfully inhibits tumor progression in A549 lung cancer xenograft mouse models.

6. Supramolecular Containers & Mesoporous Silica

• Acyclic Cucurbit[n]uril Containers: Supramolecular acyclic cucurbit[n]uril molecular containers solubilize albendazole, enabling systemic intravenous delivery of effective therapeutic doses that suppress SK-OV-3 ovarian xenograft tumors.

• PEGylated Mesoporous Silica (MCM-41): \(\beta\)-Lactoglobulin-modified and PEGylated mesoporous silica nanoparticles serve as nanostructured vehicles for targeted delivery of fenbendazole into prostate cancer cells.

  ---

The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs

Son DS, Lee ES, Adunyah SE. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs. Immune Netw. 2020 Aug 4;20(4):e29. doi: 10.4110/in.2020.20.e29. PMID: 32895616; PMCID: PMC7458798.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7458798/pdf/in-20-e29.pdf

This is a highly technical summary of the research article from Sanare Lab by Dr. Andrew Ellison, MD, July 1, 2026.

Fenbendazole protocols specifically for lung cancer treatment. Dosing strategies, combination therapies, patient case studies, and mechanisms targeting non-small cell and small cell lung cancers.

Ultimately, the source serves as an informational guide on dosing protocols and safety monitoring while emphasizing that these experimental strategies must not replace conventional medical care.

Preclinical research evaluates fenbendazole across five primary mechanisms targeting cancer cells:

1. Microtubule Destabilization & G2/M Phase Arrest

• Colchicine-Site Binding: Fenbendazole binds to β-tubulin at the colchicine-binding site, disrupting microtubule polymerization.

• Mitotic Spindle Disruption: By preventing proper mitotic spindle assembly, it induces G2/M cell cycle arrest—halting cancer cells at the transition between DNA replication and mitosis—which triggers mitotic catastrophe and apoptosis.

• Contrast with Taxanes: Unlike taxane chemotherapy drugs (e.g., paclitaxel) that stabilize microtubules, fenbendazole functions as a moderate microtubule-destabilizing agent.

2. Disruption of Glucose Metabolism (Warburg Effect)

• Downregulation of GLUT4 & HK II: Fenbendazole significantly reduces the expression of glucose transporter type 4 (GLUT4) and hexokinase II (HK II), the enzyme catalyzing the first committed step of glycolysis.

• Metabolic Starvation: Cancer cells rely heavily on accelerated glycolysis for energy (the Warburg effect). By blocking glucose uptake, fenbendazole starves tumor cells through a metabolic pathway that functions independently of microtubule disruption.

3. p53 Stabilization & Mitochondrial Apoptosis

• Mdm2/MdmX Downregulation: Fenbendazole stabilizes the tumor suppressor protein p53 by downregulating its inhibitory regulators, Mdm2 and MdmX.

• MOMP Cascade: It promotes p53 translocation to the mitochondria, activating pro-apoptotic Bcl-2 family proteins (Bax and Bak). This leads to mitochondrial outer membrane permeabilization (MOMP), cytochrome release, and caspase-mediated apoptosis.

• Subtype Limitations: This mechanism requires functional (wild-type) p53, which is present in roughly 50% of non-small cell lung cancers (NSCLC). In small cell lung cancer (SCLC), where p53 is mutated or deleted in >90 of cases, this specific p53-dependent pathway may be non-operational.

4. Induction of Ferroptosis

• Non-Apoptotic Cell Death: Emerging research indicates fenbendazole induces ferroptosis—an iron-dependent cell death pathway characterized by reactive oxygen species (ROS) accumulation and membrane lipid peroxidation.

• Overcoming Apoptosis Resistance: Because ferroptosis differs from apoptosis, necroptosis, and autophagy, it allows fenbendazole to remain active in cells resistant to conventional apoptotic signaling.

5. Independence from P-Glycoprotein (P-gp) Efflux

• Bypassing Multidrug Resistance: Fenbendazole is neither a substrate nor an inhibitor of P-glycoprotein (P-gp), the ATP-binding cassette pump that tumor cells overexpress to pump out chemotherapy drugs.

• Sustained Efficacy: Because it avoids P-gp-mediated efflux, fenbendazole retains cytotoxicity in multidrug-resistant cancer cells that no longer respond to drugs like paclitaxel or vinblastine.

6. Metabolic Trapping with DADA (Diisopropylamine Dichloroacetate)

• Dual Metabolic Blockade: Combining fenbendazole with DADA creates a convergent metabolic trap. Fenbendazole blocks glucose entry via GLUT4/HK II inhibition, while DADA inhibits pyruvate dehydrogenase kinase (PDK), forcing cells into oxidative phosphorylation that they cannot sustain.

• Preclinical Tumor Regression: In A549 NSCLC xenograft models, the FBZ + DADA combination achieved a 50% complete tumor regression rate (compared to 0% for FBZ alone) without causing liver enzyme elevation, weight loss, or organ toxicity.

Fenbendazole for Lung Cancer: Comprehensive Research Review 2026

By Dr. Andrew Ellison, MD, July 1, 2026. Science editor and health researcher at Sanare Lab

https://www.sanarelab.science/fenbendazole-lung-cancer/

This article is for research and informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any supplement, especially alongside cancer treatment.

This is text and information taken from the ClinicalTrials.gov website. If you want more details, please visit the link https://clinicaltrials.gov/find-studies/for-patients/how-to-join

How to Join a Study

You can’t sign up for a study from ClinicalTrials.gov, but you can find the information you need to contact the study. If you need help, contact your health care provider.

Find a study. (see How to Search for Clinical Studies)

• Search using the filters on the home page of ClinicalTrials.gov.

Tips:

• Search for a study about a disease or health condition using the Condition/disease filter. Enter and search for one condition at a time.

• In the Location filter, enter your address or zip code, then use the radius bar to search for clinical studies within a certain distance of where you live.

• Under the More Filters menu, find the Eligibility Criteria (participation criteria) and search for studies that match your age, sex, and gender.

To find studies looking for participants, go to Study Status and select “Recruiting and not yet recruiting studies.”

Review the list of studies you found on the Search Results page and select the ones that interest you. (see How to Use Search Results)

• After you run a search, scroll through the list of studies. You can add or remove filters if your list is too long or too short.

Open the study record and review the study details. (see How to Read a Study Record)

• Check the Participation Criteria section to see whether you might match the study based on your age, sex, and health condition. Ask your health care provider about the participation criteria and other study details to make sure the study is right for you.

Look in the Contacts and Locations section to:

• See if there is a study location that works for you

• See if there is a central contact or contact at a specific location

Once a study has completed adding new participants, contact information will no longer appear in the study record.

• Call or email the central contact or the contact at a specific location to learn more about the study and options for joining.

• Sometimes, the information on a study record is not up to date. If you don’t hear back from the study contact, you can try again, or the study may be completed, and the information has not yet been updated on ClinicalTrials.gov. If you still need help, you can ask your health care provider.

• Note that ClinicalTrials.gov is not responsible for the information on the study record, where studies are done, or what research is being conducted.

A critical issue with benzimidazoles such as fenbendazole and mebendazole is their poor water solubility, which can limit how well the body absorbs them. Many scientific resources are exploring ways to overcome this challenge. Here’s one example.

The poor aqueous solubility of the core benzimidazole scaffold is a primary factor contributing to its low and variable gastrointestinal absorption. Salt-based formulations may help overcome these pharmacokinetic limitations through several key mechanisms.

New patent applications and patented benzimidazole formulations are addressing a major biopharmaceutical challenge for this drug class: poor aqueous solubility and inconsistent oral absorption.

Here’s a quick review detailing how these newer salt-based formulations may improve solubility and in vivo performance:

1. Direct Chemical Modification and Solubilization

• Cost-Effective Salification: The patented salt forms are produced through a direct, inexpensive chemical modification of the parent benzimidazole scaffold.

• Overcoming Solubility Limits: Parent benzimidazoles possess an inherently hydrophobic structure that resists dissolving in water, leading to inconsistent absorption in the digestive tract. Converting these compounds into saline salt forms directly increases their aqueous solubility.

2. Improved In Vivo Bioavailability and Therapeutic Efficacy

• Facilitated Oral Delivery: The marked increase in water solubility enables these compounds to be administered far more easily as oral doses in animal and future clinical studies.

• Validated In Vivo Performance: In preclinical animal studies using mice experimentally infected with secondary cystic echinococcosis, the novel albendazole salt formulations showed superior aqueous solubility, enhanced systemic bioavailability, and higher therapeutic efficacy in vivo than the parent drugs.

3. Experimental Handling and Broader Delivery Context

• Enhanced Laboratory Handling: Beyond systemic absorption in vivo, the salified derivatives exhibit improved handling characteristics during in vitro cell viability assays and HPLC analytical procedures.

• Alternative to Complex Delivery Platforms: These patented saline salts offer a simple chemical alternative to other complex drug-delivery systems designed to address benzimidazole solubility, such as cyclodextrin inclusion complexes, soluble prodrugs, polymorphic solvates, and microemulsions.

The following patent application appears to have expired. However, after reviewing Google Patents, we can find others still in the works. Some combine benzimidazoles with lipids, salts, and other approaches that attempt to create novel solutions for making fenbendazole more soluble.

WO2017021992A1 — “Salts of compounds having a benzimidazolic structure, uses and process for the preparation thereof”

The patent covers salts of anthelmintic (antiparasitic) compounds that have a benzimidazole structure. The named compounds include albendazole (ABZ), fenbendazole (FBZ), triclabendazole (TRBZ) and its sulphoxides, flubendazole (FLZ), mebendazole (MBZ), oxibendazole (OBZ), thiabendazole (TBZ), and cambendazole (CBZ). These are drugs widely used to treat parasitic worm infections in both human and veterinary medicine.

A few key details:

The applicants/assignees are Italian research institutions: the Istituto Superiore di Sanità (ISS), Università degli Studi di Roma “La Sapienza,” and another university. It was filed on August 4, 2016, as PCT application PCT/IT2016/000191, with the international publication on February 9, 2017.

The chemistry is classified under benzimidazole heterocyclic compounds (C07D235 series). The general problem these salts address is that benzimidazole anthelmintics are notoriously poorly water-soluble, which limits their bioavailability; converting them into salt forms is a common strategy to improve solubility, dissolution, and therefore therapeutic performance.

One notable follow-on: some of the inventors (Simone Carradori, Adriano Casulli, Roberto Cirilli) have since worked on repurposing these benzimidazole anthelmintics and their enantiomers as candidate anticancer agents, which is an active area of “drug repurposing” research.

1. Metastatic Triple Negative Breast Cancer

2. Pediatric Glioma

These trials are in various stages of completion. You may want to enter one, or you may just want to follow the results or learn more.

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

NCT05318469 · RECRUITING · PHASE1/PHASE2 · posted 2022-04-08 · updated 2026-08-05

https://clinicaltrials.gov/study/NCT05318469

Last Update Posted 2026-08-05, Study Start (Actual) 2023-10-13, Primary Completion (Estimated) 2026-10

This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic).

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01837862 · ACTIVE_NOT_RECRUITING · PHASE1/PHASE2 · posted 2013-04-23 · updated 2026-08-06, Study Completion (Estimated) 2027-12

https://clinicaltrials.gov/study/NCT01837862

[Active, not recruiting; No longer looking for participants]

This is a study to determine the safety and efficacy of the drug mebendazole when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.

Any discussion of fenbendazole or other drugs in the benzimidazole class should be based on medical research and evidence—not social media videos or anecdotal claims.

Benzimidazole drugs have been extensively studied, particularly as antiparasitic medications. Mebendazole, for example, has been used safely in humans for decades and has a well-established safety profile. Fenbendazole has also been studied extensively in veterinary medicine as an antiparasitic drug. Because of these characteristics, researchers have investigated whether benzimidazole drugs could be repurposed for cancer treatment.

However, it is important to distinguish between scientific interest and proven cancer treatment. Fenbendazole is a veterinary deworming medication and has not been approved for use in humans to treat cancer. Evidence that it can safely and effectively treat cancer in humans remains insufficient.

Two important points to remember

1. Absorption matters.
Fenbendazole has very low water solubility, which can affect how well the body absorbs it. Its absorption may vary depending on factors such as formulation and what is present in the gastrointestinal tract. This does not mean that simply combining it with other substances makes it an effective cancer treatment.

2. More is not necessarily better.
With any drug, dose matters. Increasing the dose does not automatically make a medication more effective and can increase the risk of adverse effects or toxicity. A dose that is safe in one context may not be safe in another.

Mebendazole and fenbendazole should also not be treated as interchangeable simply because they belong to the same chemical class. Mebendazole is an antiparasitic medication used in humans, while fenbendazole is primarily a veterinary medication.

Fenbendazole has attracted considerable attention because it is inexpensive and widely available for veterinary use. Anecdotal reports from people using it for cancer continue to circulate online, but anecdotes are not a substitute for controlled clinical evidence. Laboratory and animal findings can provide useful leads for research, but they do not establish that a treatment is safe or effective in humans.

For people who lack access to cancer care or cannot afford conventional treatment, the appeal of inexpensive alternatives is understandable. However, limited access to medical care makes it even more important to separate what is known from what is hoped for. Self-administering an unapproved drug can carry real risks, including unknown dosing, drug interactions, side effects, and delaying treatments that have demonstrated benefits.

Just the facts.

Before taking any medication outside its approved use, learn what the human evidence actually shows. Look for clinical studies, safety data, known drug interactions, and information from qualified medical professionals—not just testimonials or social media posts.

If you are considering fenbendazole or another off-label or alternative treatment, discuss it with your doctor whenever possible. If you disagree with your doctor’s recommendation, seeking a qualified second opinion can be a reasonable next step.

The goal should always be the same: make treatment decisions based on the best available medical evidence, understand the risks, and avoid confusing anecdotal claims with established medical facts.

The fenbendazole scandal was a highly controversial public health event in South Korea that began in late 2019 and intensified throughout 2020. It serves as a representative example of how false and unverified cancer information regarding complementary and alternative medicine (CAM) can rapidly spread and disrupt the cancer information market.

The incident centered around the widespread, unverified belief that fenbendazole—an over-the-counter veterinary dewormer used to treat parasites in dogs—could cure terminal lung cancer. This rumor sparked national confusion, leading to the drug selling out at pharmacies across South Korea as desperate patients rushed to get it.

1. The Origin: Joe Tippens and the “Kitruda” Misunderstanding

The scandal originated with claims made by an American cancer patient, Joe Tippens, who asserted that veterinary fenbendazole had cured his terminal lung cancer. However, public media and online communities largely omitted a critical clinical detail: Tippens was also participating in a clinical trial for Kitruda (an immuno-oncology drug) at the MD Anderson Cancer Center.

The narrative that fenbendazole was a standalone “miracle cure” took root.

2. The South Korean Catalyst: Comedian Kim Chul-min

Although the rumor started in the United States, it became a major social phenomenon in South Korea because of celebrity influence. Kim Chul-min, a beloved Korean comedian suffering from lung cancer, announced on social media in September 2019 that he was taking fenbendazole to treat his illness.

At the beginning of the issue, Korean health authorities and medical experts immediately issued press releases warning the public about severe potential side effects, but desperate patients largely ignored them, focusing instead on Kim’s journey.

The timeline of Kim’s public self-treatment illustrates the tragic trajectory of the scandal:

• September 2019: Kim announced his intention to take fenbendazole.

• September 2020: After a year of self-treatment, Kim publicly declared that the drug was ineffective, announced he was stopping his self-medication, and warned other patients not to take it.

• December 2021: Kim Chul-min sadly passed away from his illness.

3. Media Failures and Fragmented Information

A qualitative study utilizing focus group interviews with 21 lung cancer patients exposed severe systemic failures in how health information was reported by the media.

While patients daily sought general cancer information from dedicated internet communities, they passively encountered the fenbendazole rumor through traditional television news and broadcasts. However, this media coverage was highly fragmented and lacked depth:

• Chemotherapy Omission: An overwhelming majority of interviewed patients believed that Kim Chul-min was treating his cancer exclusively with the dog dewormer. TV headlines heavily sensationalized the dewormer but completely failed to mention that Kim was concurrently undergoing standard hospital chemotherapy.

• Lack of Source Verification: Only a tiny fraction of patients actively cross-checked the original source videos on YouTube to discover that Joe Tippens was also undergoing concurrent immunotherapy. The rest relied on simplified, sensationalized snippets broadcast on television and internet portals.

4. Patient Psychology and the “What If” Factor

The focus groups revealed a profound psychological conflict among cancer patients. While most patients rationally understood that fenbendazole was medically unverified and lacked scientific backing, their terminal diagnoses bred a desperate “what if” hope:

“When I hear a story like someone ate something and recovered … it sparks the hope for ‘what if’. Even with the slightest hope like this, I want to try it.”

This desperation caused patients to actively ignore official medical warnings. Because they felt a lack of guidance on self-care and immune-boosting protocols at home, they took matters into their own hands:

• Subjective Filtering: Patients created their own arbitrary guidelines based on “common sense” or gut feelings to determine if an online rumor was an exaggerated commercial.

• Self-Clinical Testing: Desperate patients used their own bodies as testing grounds, trying the drug and monitoring their own physical reactions to gauge success. For example, one patient in the study noted that they ultimately had to stop taking fenbendazole because it was damaging their liver.

5. The Role of “YouTube Journalism”

The study highlighted that YouTube has evolved into a uniquely powerful, active search channel for patients. While patients initially heard about fenbendazole passively on TV, they immediately turned to YouTube to search for personal testimonials, patient diaries, and alternative opinions.

Because YouTube lacks the strict peer-review or verification of professional medicine, the highly emotional “evidence of experience” shared by other patients often completely overrode the scientific warnings of the medical community.

6. Political and Policy Repercussions

The social chaos and panic surrounding the dewormer were so severe that the fenbendazole scandal was raised during South Korea’s 2020 parliamentary audit of the Ministry of Health and Welfare.

Researchers and policy experts concluded that health authorities must transition away from slow, reactive press releases and instead establish preemptive, user-centered communication networks. The study recommended that governments actively monitor online platforms, collaborate with medical experts to quickly verify trending CAM claims, and work with video platforms to introduce verification labels that help vulnerable patients distinguish expert medical advice from unverified personal anecdotes.

ORIGINAL RESEARCH article:

How cancer patients get fake cancer information: From TV to YouTube, a qualitative study focusing on fenbendazole scandle

Front. Oncol., 27 October 2022

Sec. Cancer Epidemiology and Prevention

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.942045

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.942045/full

In translational medicine, we often view progress as a linear race to invent something entirely “new.” However, some of the most profound breakthroughs in oncology come from looking backward at the medicines already in our cabinets. This is drug repurposing—the scientific art of identifying new therapeutic applications for established, clinically approved drugs.

1. The Starting Point: Why We Look for Shortcuts

Developing a de novo drug is a monumental task often compared to finding a needle in a haystack—while the haystack is on fire and costs billions to search. Drug repurposing offers a strategic “shortcut” by leveraging our existing knowledge of a medicine’s safety profile.

The Inherent Advantages of Repurposing

For a patient, these advantages are the difference between waiting decades or months for a treatment:

• Proven Safety Profiles: Because these drugs are already FDA-approved, we have extensive longitudinal data on human toxicity and pharmacokinetics.

• Established Dosage Guidelines: Clinical educators and practitioners don’t have to start from zero; we already understand the human body’s tolerance levels.

• Accelerated Development: By bypassing early safety trials, we dramatically expedite the transition from the laboratory bench to the patient’s bedside.

Because traditional discovery is prohibitively slow and expensive, we must act as scientific detectives, using creative hypothesis generation to uncover the “hidden” cancer-fighting properties of established medicines.

2. Phase I: Generating the Hypothesis (The Spark)

How do we decide that a drug for alcoholism or arthritis might actually treat a tumor? The journey begins with a spark of data-driven logic.

The Three Stages of the Repurposing Journey

1. Hypothesis Generation: Identifying “core targets” of the disease and matching them to an existing drug’s profile.

2. Efficacy Testing: Validating that the drug works in controlled laboratory environments (in vitro and in vivo).

3. Clinical Trials: Moving directly into Phase II human trials once the safety data from the drug’s original use is confirmed.

Finding the Candidates

We utilize two primary methodologies to identify potential candidates:

3. Phase II: The Scientist’s Lab (The Tools of Discovery)

In this phase, we use advanced models to simulate the human body. Two of the most powerful tools in our arsenal are Tumoroids and Phenotypic Screening.

Tumoroids: The “Mini-Organs”

A tumoroid is a specialized type of cancer organoid—an in vitro 3D tissue grown from a patient’s own cells.

• Why they mimic real tumors:

  • Architecture: They grow in complex 3D structures rather than flat layers.

  • Genetic Profile: They retain the patient’s specific DNA mutations.

  • Mutational Landscape: They maintain the original tumor's biological diversity.

  • Therapeutic Response: They react to drugs with high fidelity to the patient’s actual clinical response.

Critical Thinking Note: As educators, we must recognize that while tumoroids are a massive leap forward, they currently lack vascularization and the complex Tumor Immune Microenvironment (TIME), such as immune and neural cells. They are a vital step toward patient reality, but not a full replacement.

Phenotypic Screening: Function-First

Rather than focusing on a single gene, scientists watch how a drug changes the cancer's “phenotype” (its physical behavior).

Case Study: Calcium Channel Blockers (CCBs) Originally indicated for hypertension and heart conditions, CCBs like Amlodipine, Felodipine, Dicloamanidipine, and Cilidipine underwent a phenotypic screen. Scientists found they inhibited filopodia formation—the “fingers” cancer cells use to crawl. This proved these heart drugs could physically prevent cancer cell invasion.

Once a tool proves a drug can work, we must map exactly where it attacks the cancer’s survival strategy.

4. Mapping the Target: The 14 Hallmarks of Cancer

Cancer is no longer viewed as a single disease, but a set of 14 updated hallmarks or survival behaviors. Repurposed drugs are chosen because they “flip the switch” on these specific behaviors.

Flipping the Switch: The Tumor Microenvironment (TME)

Cancer cells create “neighborhoods” (TMEs) that hide them from the immune system. We use repurposed drugs to disrupt these niches:

• Acidic Niche: Tumors are more acidic (pH 6.4–7) than healthy tissue. Proton Pump Inhibitors (PPIs) can neutralize this acidity, making chemotherapy more effective and preventing immune evasion.

• Hypoxic Microenvironment: Tumors thrive in low-oxygen zones. Ascorbic Acid (Vitamin C) has been shown to decrease the expression of HIF-1α, the protein that helps tumors survive without oxygen.

• Microbial Microenvironment: Gut bacteria can dictate treatment success. Inulin reshapes the gut’s “polymorphic microbiome,” boosting the immune system’s natural attack on the cancer.

While the lab results look promising, the journey from bench to bedside is fraught with practical obstacles.

5. Phase III: The Reality Check (Challenges & Clinical Trials)

Even a biologically “perfect” drug faces massive hurdles before it can be prescribed in an oncology ward.

Hurdles to Clinical Adoption

• Intellectual Property (IP) Rights:

  • Student Insight: When a drug is “off-patent,” pharmaceutical companies have little financial incentive to fund the $100M+ trials required for a new indication, even if the drug is highly effective.

• Dosage and Toxicity (The “Off-Target” Risk):

  • Student Insight: The dose required to kill a tumor may be much higher than the dose used for the drug’s original purpose. For example, using statins or metformin at oncology-level doses risks inducing severe hypolipidemia or hypoglycemia in patients.

• Regulatory Barriers:

  • Student Insight: Formal global guidance and incentives are currently lacking to help researchers navigate approval of “old” drugs for “new” life-saving roles.

Clinical Trial Spotlight

These drugs are currently undergoing the “reality check” of human testing:

• Metformin: Testing against Breast, Pancreas, and Prostate cancers.

• Statins: Testing against Gastric and Colorectal cancers.

• Celecoxib: Testing against Melanoma and postoperative Recurrent Gastric cancer.

These challenges are significant, but emerging delivery technologies like nanotechnology are helping us bypass dosage and toxicity limitations.

6. The Horizon: The Future of Repurposing

The future of this field lies in precision. We are no longer just finding the right drug; we are building better “delivery vehicles” for them.

Nanotechnology: Precision Topical Drug Delivery

Nanoparticles (liposomes, micelles, or metallic particles) act as microscopic envelopes that carry repurposed drugs directly to the tumor.

• The EPR Effect: We utilize the Enhanced Permeability and Retention (EPR) effect, where nanoparticles naturally accumulate in the “leaky” vasculature of tumor tissue while bypassing healthy cells.

• Reducing Side Effects: By “shielding” the drug until it reaches its target, we prevent it from accumulating in the kidneys or spleen, effectively lowering the systemic toxicity of high-dose treatments.

• Increasing Bioavailability: Many repurposed drugs (like Curcumin or Niclosamide) have poor water solubility; nanotechnology keeps them stable in the bloodstream until they reach the tumor site.

Final Insight: The Renaissance of Medicine

Drug repurposing represents a true “Renaissance” in medicine. It teaches us that the solutions to our most complex modern challenges might already be in our hands. By combining traditional medicinal wisdom, 20th-century pharmacology, and 21st-century nanotechnology, we are creating a more hopeful, faster, and more affordable future for cancer patients worldwide.

Drug repurposing for cancer therapy, April 2024

Signal Transduction and Targeted Therapy 9(1) DOI:10.1038/s41392-024-01808-1

https://www.researchgate.net/publication/379911710_Drug_repurposing_for_cancer_therapy

You are invited to join a live webinar Q&A session with me, Joe.

https://streamyard.com/watch/g34DqDxrninN

I've kept asking questions, learning more, and doing research, which has led to clearer information about my thoughts and experiences. Come see for yourself.

Live Webinar Question & Answer Session:

Thursday, August 20th at 2 pm CST (3:00 PM East Coast Time)

Please use this link to register - CLICK HERE or the image below

https://streamyard.com/watch/g34DqDxrninN

Joe does Q&A sessions occasionally, and they've been very helpful — it's great to hear what he has to say. His declaration about fenbendazole sparked a global media blitz and raised worldwide awareness, and you can listen in live for free.

The Hidden Hero: A Pharmacy Shelf Disruptor

Science often finds its most profound breakthroughs in the most mundane places. Imagine a common, low-cost medication—one typically prescribed to treat childhood pinworms or hookworms—holding the potential to combat one of the world’s most aggressive malignancies. This is the intriguing reality of drug repurposing, a strategy that could disrupt the high-cost, high-stakes world of oncology.

The necessity for such disruption is clear. Gastric cancer remains a global titan of mortality, ranking as the second leading cause of cancer-related deaths worldwide. For many, the diagnosis is a late-stage revelation; two-thirds of patients already have locally advanced or metastatic disease by their first consultation. With a five-year survival rate hovering at a dismal 20%, the medical community is desperate for new weapons, particularly to treat “malignant ascites”—a condition where fluid teeming with cancer cells accumulates in the abdomen, signaling a highly resistant and advanced stage of the disease.

Fast-Tracking the Frontline: The Logic of Repurposing

Mebendazole (MBZ) is an FDA-approved anthelmintic that has been a staple in medicine for decades. While its primary role involves clearing the gut of parasites like roundworms and hookworms, researchers are now pivoting its use toward human malignant ascites derived from stomach cancer.

The logic of repurposing is both an economic and clinical masterstroke. Developing a novel oncology drug from scratch can cost billions and span decades. MBZ, however, is a “known quantity.” It is orally available, exceptionally low-cost, and carries a proven safety profile. By using a drug that has already cleared the rigorous hurdles of human safety testing, researchers can skip years of early-phase trials and fast-track treatment to patients in need.

“There is an urgent need to introduce new therapeutic agents in the management of peritoneal carcinomatosis.”

The Potency Gap: Outperforming the Gold Standards

In a head-to-head laboratory showdown, the data revealed a shocking “potency gap” between this humble dewormer and the titans of clinical chemotherapy. To measure efficacy, researchers look at the IC50—the concentration of a drug required to kill 50% of cancer cells. In this metric, a lower number signifies a more powerful punch.

The results from the study were staggering. In the aggressive ACP-02 (Diffuse type) gastric cancer line, MBZ achieved an IC50 of just 0.39 μM. When compared to the clinical “gold standards,” the disparity was undeniable:

• 5-Fluorouracil (5-FU): 19.71 μM

• Cisplatin: 15.82 μM

• Oxaliplatin: 8.85 μM

To put this in perspective, MBZ was nearly 50 times more potent than 5-FU in these specific cells. Even in the ACP-03 (Intestinal type) line, which showed more resistance, MBZ maintained a potent IC50 of 1.25 μM, still outclassing traditional regimens. Furthermore, the study uncovered a powerful synergy: when MBZ was combined with 5-FU, the IC50 dropped to 0.38 μM, suggesting that MBZ doesn’t just work alone—it makes existing treatments better.

A Biological Siege: Dismantling the Cancer Skeleton

MBZ’s effectiveness stems from its ability to launch a biological siege on the cancer cell’s internal architecture. Much like how it kills parasites by disrupting their gut lining, MBZ attacks the “skeleton” of the cancer cell—specifically its microtubule structure.

Microtubules are essential scaffolding; without them, a cell cannot maintain its shape, transport nutrients, or successfully divide. By preventing the tubulin protein from polymerizing, MBZ essentially causes the cell’s internal framework to collapse. This mechanism is remarkably similar to high-end, expensive chemotherapy drugs like Paclitaxel.

The visual evidence of this collapse is striking. In immunofluorescence staining (as seen in [SOURCE_IMAGE_1]), vehicle-treated control cells (Image A) show organized, discrete networks of microtubules. In contrast, the MBZ-treated cells (Images D, E, and F) show a total microtubular disarray, with the internal architecture replaced by diffuse, disorganized staining. The cell’s skeleton isn’t just damaged; it is dismantled.

Cutting Off the Escape Route: Thwarting Metastasis

For patients with advanced gastric cancer, the primary cause of death is not the initial tumor, but “peritoneal metastasis”—the cancer’s ability to migrate and invade other tissues. MBZ appears to serve as a roadblock for this spread.

A key molecular breakthrough in this research involves MMP-2 (Matrix Metalloproteinase 2). Think of MMP-2 as a “molecular machete” that cancer cells use to hack through the basement membrane and extracellular matrix, clearing a path to invade surrounding organs. The study found that MBZ significantly reduced the activity of this enzyme, effectively dulling the cancer’s blade.

“MBZ was effective in reducing the activity of MMP-2... suggesting its action in inhibiting the invasion of cancer cells.”

By inhibiting this “machete,” MBZ potentially keeps the cancer localized, preventing the very spread that makes advanced gastric cancer so lethal.

Breaking the Toxicity Status Quo

Perhaps the most compelling argument for MBZ is the “win” for patient safety and global accessibility. Traditional chemotherapy regimens like 5-FU and cisplatin are notorious for their toxic toll, often causing myelosuppression (the suppression of bone marrow) and severe gastrointestinal distress.

MBZ offers a starkly different profile. It is a low-cost, orally available medication with a “remarkable safety profile” and “reduced toxicity to normal cells.” This suggests its potential as an adjuvant therapy—a secondary agent that can be added to standard treatments to increase their kill rate without adding to the patient’s toxic burden. In a world where cancer care is increasingly defined by multi-million dollar price tags, a treatment that is both safe and affordable is the ultimate innovation.

Conclusion: The Path to the Clinic

These findings offer a beacon of hope for the management of advanced gastric cancer. By killing malignant cells with high potency, disrupting their structural integrity, and halting their spread through enzyme inhibition, MBZ has proven itself a formidable candidate for the clinical stage.

However, a journalistic dose of caution remains: these results were observed in vitro. While the laboratory data is overwhelming, “clinical trials must be performed” to confirm if this dewormer can replicate its success in human patients.

As we look toward the future of oncology, we must ask ourselves a critical question: In our search for the next multi-billion dollar breakthrough, have we been overlooking the powerful, life-saving solutions already sitting on our pharmacy shelves?